Sio Gene Therapies (Sio Gene Therapies) Growth Rank : 0 (As of Apr. 30, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Sio Gene Therapies Growth Rank?

Sio Gene Therapies has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Sio Gene Therapies Growth Rank Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Sio Gene Therapies (Sio Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

130 West 42nd Street, 26th Floor, New York, NY, USA, 10036

Website

https://www.siogtx.com

Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.

Executives

Parag V Meswani	officer: Chief Commercial Officer	130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu	officer: Chief Executive Officer	C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif	officer: Principal Financial Officer	C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo	10 percent owner	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado	10 percent owner	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc	10 percent owner	1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901